Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Importance: Changes in postsurgical opioid prescribing practices may help reduce chronic opioid use in surgical patients.

Objective: To investigate whether postsurgical acute pain across different surgical subspecialties can be managed effectively after hospital discharge with an opioid supply of 3 or fewer days and whether this reduction in prescribed opioids is associated with reduced new, persistent opioid use.

Design, Setting, And Participants: In this prospective cohort study with a case-control design, a restrictive opioid prescription protocol (ROPP) specifying an opioid supply of 3 or fewer days after discharge from surgery along with standardized patient education was implemented across all surgical services at a tertiary-care comprehensive cancer center. Participants were all patients who underwent surgery from August 1, 2018, to July 31, 2019.

Main Outcomes And Measures: Main outcomes were the rate of compliance with the ROPP in each surgical service, the mean number of prescription days and refill requests, type of opioid prescribed, and rate of conversion to chronic opioid use determined via a state-run opioid prescription program. Postsurgical complications were also measured.

Results: A total of 4068 patients (mean [SD] age, 61.0 [13.8] years; 2528 women [62.1%]) were included, with 2017 in the pre-ROPP group (August 1, 2018, to January 31, 2019) and 2051 in the post-ROPP group (February 1, 2019, to July 31, 2019). The rate of compliance with the protocol was 95%. After implementation of the ROPP, mean opioid prescription days decreased from a mean (SD) of 3.9 (4.5) days in the pre-ROPP group to 1.9 (3.6) days in the post-ROPP group (P < .001). The ROPP implementation led to a 45% decrease in prescribed opioids after surgery (mean [SD], 157.22 [338.06] mean morphine milligram equivalents [MME] before ROPP vs 83.54 [395.70] MME after ROPP; P < .001). Patients in the post-ROPP cohort requested fewer refills (367 of 2051 [17.9%] vs 422 of 2017 [20.9%] in the pre-ROPP cohort; P = .02). There was no statistically significant difference in surgical complications. The conversion rate to chronic opioid use decreased following ROPP implementation among both opioid-naive patients with cancer (11.3% [143 of 1267] to 4.5% [118 of 2645]; P < .001) and those without cancer (6.1% [19 of 310] to 2.7% [16 of 600]; P = .02).

Conclusions And Relevance: In this cohort study, prescribing an opioid supply of 3 or fewer days to surgical patients after hospital discharge was feasible for most patients, led to a significant decrease in the number of opioids prescribed after surgery, and was associated with a significantly decreased conversion to long-term opioid use without concomitant increases in refill requests or significant compromises in surgical recovery.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857779PMC
http://dx.doi.org/10.1001/jamaoncol.2022.6278DOI Listing

Publication Analysis

Top Keywords

opioid
13
chronic opioid
12
opioid prescription
12
restrictive opioid
8
opioid prescribing
8
opioid supply
8
supply fewer
8
fewer days
8
ropp opioid
8
august 2018
8

Similar Publications

Medications for Opioid Use Disorder in County Jails - Outcomes after Release.

N Engl J Med

September 2025

Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst.

Background: In 2019, seven county correctional facilities (jails) in Massachusetts initiated pilot programs to provide all Food and Drug Administration-approved medications for opioid use disorder (MOUD).

Methods: This observational study used linked state data to examine postrelease MOUD receipt, overdose, death, and reincarceration among persons with probable opioid use disorder (OUD) in carceral settings who did or did not receive MOUD from these programs from September 1, 2019, through December 31, 2020. Log-binomial and proportional-hazards models were adjusted for propensity-score weights and baseline covariates that remained imbalanced after propensity-score weighting.

View Article and Find Full Text PDF

Childbirth-Related Posttraumatic Stress Disorder (CB-PTSD) can arise even after low-risk deliveries. This case report describes a 35-year-old woman who, despite a medically uncomplicated vaginal birth, developed severe CB-PTSD after being denied neuraxial analgesia and receiving remifentanil-PCA (remi-PCA) to manage pain. Her distress stemmed from inadequate pain relief, dissociation, and loss of control, exacerbated by unmet expectations for epidural analgesia.

View Article and Find Full Text PDF

Firefighters often serve as emergency medical services providers and face repeated exposure to potentially traumatic events (PTEs) while participating in opioid overdose responses (OORs), which may impact their mental health. A survey of 173 firefighters who had participated in an OOR in the previous 6 months was used to assess exposure to PTEs during such events, job stress, mental health symptoms, and resources used to address mental health symptoms. Most firefighters (97%) reported experiencing one or more PTEs while responding to an opioid overdose in the past 6 months.

View Article and Find Full Text PDF

Purpose: Postoperative hyperalgesia (POH) is a common clinical phenomenon that will increase the experience of patients' pain. Previous studies have confirmed that surgical site, opioid analgesics, gender, and age were risk factors of POH. Limited research has been investigated to prove the association between obstructive sleep apnea (OSA) and POH.

View Article and Find Full Text PDF

Contingency Management for Stimulant Use Disorder and Association With Mortality: A Cohort Study.

Am J Psychiatry

September 2025

Michigan Innovations in Addiction Care Through Research and Education (MI-ACRE) Program, Department of Psychiatry, University of Michigan, Ann Arbor.

Objective: While opioid overdose has begun to decrease in recent years, stimulant overdose has continued to increase and has not been adequately addressed. Unlike opioid use disorder, there are no medications approved by the U.S.

View Article and Find Full Text PDF